Study #2023-0673
A phase 2 Study of Axicabtagene Ciloleucel and Glofitamab as second-line therapy for relapsed or refractory, or high-risk untreated patients with large B Cell Lymphoma
MD Anderson Study Status
Enrolling
Treatment Agent
Glofitamab, Obinutuzumab, Axi-cel
Description
To learn if the combination of axicabtagene ciloleucel (axi-cel) and glofitamab as first-line therapy in high-risk LBCL participants or as second-line therapy in LBCL participants can help to control the disease.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
B Cell Lymphoma
Study phase:
Phase II
Physician name:
Jason Westin
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-839-0558
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.